Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Reaches New 52-Week High – Here’s Why

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) hit a new 52-week high on Tuesday . The company traded as high as $10.97 and last traded at $10.85, with a volume of 101274 shares traded. The stock had previously closed at $10.70.

Analysts Set New Price Targets

A number of research firms have commented on BAYRY. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The company has a debt-to-equity ratio of 1.04, a current ratio of 1.13 and a quick ratio of 0.73. The firm has a market cap of $42.62 billion, a PE ratio of -120.50, a PEG ratio of 5.27 and a beta of 0.69. The business has a 50-day simple moving average of $8.97 and a 200 day simple moving average of $8.34.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.